Accueil   Diary - News   All news ELSALYS BIOTECH ANNOUNCES THE REGISTRATION OF ITS DOCUMENT DE BASE IN THE CONTEXT OF ITS PROPOSED INITIAL PUBLIC OFFERING ON THE PARIS EURONEXT GROWTH® MARKET

ELSALYS BIOTECH ANNOUNCES THE REGISTRATION OF ITS DOCUMENT DE BASE IN THE CONTEXT OF ITS PROPOSED INITIAL PUBLIC OFFERING ON THE PARIS EURONEXT GROWTH® MARKET

 

 

Lyon, FRANCE, 20 April 2018, ELSALYS BIOTECH, a new player in immuno-oncology, announces the registration of its Document de Base with the Autorité des Marchés Financiers (AMF) under the number I.18-019 as at 19 April 2018.

The registration of the Document de Base is the first step in the proposed initial public offering of ELSALYS BIOTECH on the Paris Euronext Growth® market, subject to market conditions
and the granting of its visa on the Prospectus for this operation.

 

ELSALYS BIOTECH, at the heart of the new wave of immunotherapy


Today, immunotherapy is a highly dynamic market segment, and in particular its applications in immuno-oncology. Immunotherapy drug sales are estimated at $45 billion for 20251, including $30 billion as from 20202 in the sole market segment of immunomodulator antibodies in cancer.


The aim of ongoing research is to validate new mechanisms of action that are capable of combining with treatments that have already demonstrated a positive risk/benefit factor in many cancers in order to increase efficacy and to better identify patients who respond to each treatment.

The market is thus engaged in a new wave of innovation driven by combination therapies.

ELSALYS BIOTECH positions itself at the heart of this immunotherapy revolution, by developing antibodies against new therapeutic targets.

 

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree